The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy

被引：11

作者：

Dowell, Jonathan E.

Minna, John D.

机构：

[1] Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res NB8 206, Dallas, TX 75390 USA

[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA

[3] Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA

[4] Dallas Vet Affairs Med Ctr, Dallas, TX USA

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2004年 / 1卷 / 01期

关键词：

D O I：

10.1038/ncponc0007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2 / 3

页数：2

共 7 条

[1] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[2] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[3] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[4] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[5] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[6]

SHEPHERD FA, 2004, P ASCOI S, V23, P12

[7] Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways [J].

Sordella, R ;

Bell, DW ;

Haber, DA ;

Settleman, J .

SCIENCE, 2004, 305 (5687) :1163-1167

← 1 →